The Chemours Company (CC) shares saw a recent bid of $41.61 and 2.64M shares have exchanged hands in the recent trading session, yielding a -2.14% decline over the past week. The stock price increased 1.09% or $-0.45 versus $41.16 at the end of the prior session. This change led market cap to move at $7.74B, putting the price -9.58% below the 52-week high and 614.95% above the 52-week low. The company’s stock has a normal trading capacity of 2.41M shares while the relative volume is 1.09.
To stay one step ahead we extended our research by comparing different price targets. The stock notched a 12-month high of $47.00 while $55.00 target is by far the most aggressive out of analysts who are currently evaluating the company, $8 higher than the next highest 52-week price estimate. The lowest 12-month price target for the shares is $35.00, which would be decrease of about -16% of its current value. The mean target of $48.00 should be compared with the price when the stock was languishing around $5.82 a share. And it remains to be seen which target price CC can achieve without sacrificing much as the company is holding a 392.43% gain for the past twelve months.
By historical standards, The Chemours Company remains a cheap stock. The company’s current price-earnings ratio amounts to 75.87 times earnings, above the average P/E ratio of 20.21 times earnings. For now, The Chemours Company is the toast of Wall Street as its ABR stands at 2.10 with 2 out of 8 analysts rating the stock a buy. Over the short term, some market observers may have noticed that The Chemours Company has a 2.99% short float with 15 days to cover. It becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume. The Chemours Company has far performed well this year, with the share price up 88.37% since January. Over the past 2 quarters, the stock is up 69.08%, compared with a gain of nearly 23.69% for 3 months and about 4.29% for the past 30 days.
Last time, the company shocked Wall Street by reporting EPS of $0.75, smashing the consensus of $0.50 per share. Revenue for the quarter also killed consensus, coming in at $1.44B, compared to the consensus of 1.32B. Nonetheless, from here on out, earnings per share forecasts for the current quarter are $0.82. The company is expected to report EPS as high as $0.89 and as low as $0.75 per share. Similarly, full-year EPS forecasts have ranged between $3.08 and $3.45. The mean EPS estimate is $3.26. On the other side, sales forecasts for the current quarter are $1.48B. The stock is expected to report revenue as high as $1.49B and as low as $1.48B per share. Similarly, full-year sales forecasts have ranged between $5.39B and $5.97B. The mean revenue estimate is $5.73B.
Over the last 5 years, The Chemours Company has averaged a -65.60% YoY EPS growth rate and a -7.50% revenue growth rate. Analysts are expecting EPS growth rates to be at 107.70% this quarter and EPS estimate for next year reflect 21.80% growth rate.
Sell-side analysts also have something to say about this company. Susquehanna analysts stated on 15/05/2017 that they maintained their Positive rating. JP Morgan raised its rating on The Chemours Company to Overweight on 12/05/2017 in a reversal from its prior Neutral rating. Jefferies raised its rating on The Chemours Company to Buy on 29/03/2017 in a reversal from its prior Hold rating. Susquehanna raised its rating on The Chemours Company to Positive on 17/02/2017 in a reversal from its prior Neutral rating.